Effects of Ginger on Serum Lipids and Lipoproteins in Peritoneal Dialysis Patients: A Randomized Controlled Trial. Issue 2 (March 2016)

• Record Type: Journal Article
• Authors: Tabibi, Hadi; Imani, Hossein; Atabak, Shahnaz; Najafi, Iraj; Hedayati, Mehdi; Rahmani, Leila
• Is Part Of: Peritoneal dialysis international. Volume 36:Issue 2(2016)
• Page Start: 140
• Page End: 145
• Publication Date: 2016-03
• Subjects: Ginger -- peritoneal dialysis -- lipids -- lipoproteins -- cardiovascular disease; Peritoneal dialysis -- Periodicals; Continuous ambulatory peritoneal dialysis -- Periodicals; 617.461059
• DOI: 10.3747/pdi.2015.00006
• Languages: English
• ISSNs: 0896-8608

Abstract

Background: In peritoneal dialysis (PD) patients, one of the major risk factors for cardiovascular disease is lipid abnormalities. This study was designed to investigate the effects of ginger supplementation on serum lipids and lipoproteins in PD patients. Methods: In this randomized, double-blind, placebo-controlled trial, 36 PD patients were randomly assigned to either the ginger or the placebo group. The patients in the ginger group received 1, 000 mg ginger daily for 10 weeks, while the placebo group received corresponding placebos. At baseline and at the end of week 10, 7 mL of blood were obtained from each patient after a 12- to 14-hour fast, and serum concentrations of triglyceride, total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and lipoprotein (a) [Lp (a)] were measured. Results: Serum triglyceride concentration decreased significantly up to 15% in the ginger group at the end of week 10 compared with baseline ( p < 0.01), and the reduction was significant in comparison with the placebo group ( p < 0.05). There were no significant differences between the 2 groups in mean changes of serum total cholesterol, LDL-C, HDL-C, and Lp (a). Conclusion: This study indicates that daily administration of 1, 000 mg ginger reduces serum triglyceride concentration, which is a risk factor for cardiovascular disease, in PD patients.